Limacorporate S.p.A Via Nazionale 52 Di San Daniele San Daniele Del Friuli Italy TEMA Axle Small, REF 1590.15.010 (additional information is pending receipt of the firm's product label/labeling) Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
TEMA Axle Small, REF 1590.15.010 (additional information is pending receipt of the firm's product label/labeling)
Brand
Limacorporate S.p.A Via Nazionale 52 Di San Daniele San Daniele Del Friuli Italy
Lot Codes / Batch Numbers
Not specified in FDA notice. Check official source for details.
Products Sold
Product Code: 1590.15.010 UDI-DI Code: 08033390128865 Lot Number: 2115522 Sterilization Lot Number: 2100241
Limacorporate S.p.A Via Nazionale 52 Di San Daniele San Daniele Del Friuli Italy is recalling TEMA Axle Small, REF 1590.15.010 (additional information is pending receipt of the firm's product l due to Due to the incorrect component, that is not cleared to be marketed in the U.S., being included in its elbow prosthesis.. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Due to the incorrect component, that is not cleared to be marketed in the U.S., being included in its elbow prosthesis.
Recommended Action
Per FDA guidance
On or about 01/25/2023, the firm sent a "VOLUNTARY CORRECTION" Letter via email to customers informing them that the firm has become aware that it incorrectly included low constraint Tema axle small components (not cleared for marketing in U.S.) with its high constraint humeral bodies system. According to the firm's records, 3 low constraint components were implanted between 12/10/2021 to 07/05/2022. Customers are being instructed to: LimaCorporate suggests to Surgeons and Hospitals where an affected device listed in Table 1 was implanted in combination with high constraint humeral bodies components belonging to the product family 1550.15.0XX to yearly follow-up patients with radiographs and varus/valgus range-of-motion evaluation to assess for poly bushing wear. If the follow-up monitoring after 24 months from the implant date shows uneventful and no abnormality, surgeons are invited to do patient follow-up according to the standard protocols, except in case of pain subsequently experienced by the patient. In addition, customers will be instructed by the firm's U.S Regulatory Affairs Associate to post the letter in or near implanted patients' records to continuously remind surgeons and hospitals to monitor their implant patients regarding this Voluntary Correction. For questions or further assistance, contact the firm via email at medicalcomplaints@limacorporate.com.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticeDistribution
As reported by FDA
TX
Page updated: Jan 10, 2026